Skip To Main Content
Shahla Bari on Muck Rack

Shahla Bari

As seen in: UroToday, OncoDaily
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Shahla

Contact Shahla, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Perioperative immune-checkpoint inhibitors for muscle-invasive bladder cancer.

|
By Albert Jang, Abby Grier, Shahla Bari
| UroToday Verified
Muscle-invasive bladder cancer (MIBC) has a high risk of recurrence following radical cystectomy. Neoadjuvant cisplatin-based chemotherapy has been used for decades to lower recurrence rates but a significant proportion of patients still have disease relapse. Recently, immune-checkpoint inhibitors (ICIs) have been evaluated for patients with MIBC, with some success.
Open in Who Shared Issue with article?

Renee Maria Saliby: Discussing a huge clinical unmet - non-clear cell RCC

|
By Laurence Albigès, Renee Maria Saliby, Renée M. Saliby, Tian Zhang, Shahla Bari
| OncoDaily
Renee Maria Saliby, Postdoctoral GU Oncology Research Fellow at Dana-Farber Cancer Institute, shared a post by GU Oncology Now on X, adding: “It was an honor to be part of my first roundtable with Tian Zhang and Shahla Bari. Discussing a huge clinical unmet: non-clear cell RCC.
Open in Who Shared Issue with article?
See all 2 articles